Childhood Obesity Risk Markers (MARIOBE) (MARIOBE)

September 15, 2026 updated by: University Hospital, Clermont-Ferrand

Childhood Obesity Risk Markers

Metabolic diseases, including childhood obesity, represent a major public health challenge. Studies in mice have identified transcriptomic markers in adipose tissue capable of predicting a predisposition to obesity prior to any weight gain. The MARIOBE project aims to translate this approach to young children (≤ 4 years old) in order to identify individual vulnerability to obesity at an early stage.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 4 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Child scheduled for surgery allowing for the harvesting of adipose tissue.

Exclusion Criteria:

  • Child whose holders of parental authority are protected by law

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: early transcriptomic markers

during a scheduled surgery before the age of 4 years, collection of a blood sample (2.5 mL in a PAXgene tube) and two adipose tissue fragments, each measuring 5 mm x 5 mm x 5 mm.

tracking of weight and height curves from birth to age 6

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
transcriptomic markers in children under 4 years of age that predict a predisposition to being overweight at age 6 (BMI > IOTF25).
Time Frame: perioperative

Ranking of the discriminative capacity of adipocyte and blood transcripts before 4 years of age to predict the development of overweight (BMI > IOTF25) at age 6, using Partial Least Squares Discriminant Analysis (PLS-DA).

perioperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
analyze weight trajectories
Time Frame: at age 6 years

Selection and validation of transcriptomic markers for the development of a predictive score for the risk of overweight and obesity in children

at age 6 years
molecular and epigenetic mechanisms associated with the identified transcriptomic signatures.
Time Frame: at the time of blood ans adipose tissu sampling

methylation profiles

at the time of blood ans adipose tissu sampling
comparison of transcriptomic expression levels between blood and adipose tissue
Time Frame: perioperative

percentage of common markers sampled from blood and adipose tissue

perioperative
develop a quantitative test based on digital PCR to define individual expression thresholds predictive of risk
Time Frame: at age 6 years

Performance of the digital PCR test evaluated by the ability to discriminate weight trajectories (AUC of ROC curves).

at age 6 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Etienne Merlin, University Hospital, Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2036

Study Completion (Estimated)

September 1, 2036

Study Registration Dates

First Submitted

September 8, 2026

First Submitted That Met QC Criteria

September 15, 2026

First Posted (Actual)

September 21, 2026

Study Record Updates

Last Update Posted (Actual)

September 21, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RBHP 2026 MERLIN
  • 2026-A00633-48 (Other Identifier: ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe